Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

New Members of BioNJ Board Illustrate New Jersey’s Vibrant Innovation Ecosystem

3/4/2016

0 Comments

 
Trenton, NJ — Showcasing the synergy and collaboration that has become a hallmark of New Jersey’s vibrant innovation economy, BioNJ‘s newest Board members lead companies that have graduated from the New Jersey Economic Development Authority’s (EDA’s) Commercialization Center for Innovative Technologies (CCIT).
 
Bradley L. Campbell of Amicus Therapeutics and Daniel J. O’Connor of Advaxis join executives from several other EDA-supported companies that already serve on the Board of BioNJ, the trade association for the State’s life sciences industry.
 
“New Jersey’s innovation ecosystem fosters collaboration,” EDA Chief Executive Officer Melissa Orsen said. “BioNJ has been at the forefront of advocating for New Jersey’s biotechnology companies, and to see so many EDA-supported companies actively involved at this level in the industry confirms the value of our industry-focused programs.”
​BioNJ is a network of 400 member companies whose mission is to propel New Jersey’s robust life sciences ecosystem forward to accelerate the discovery, development and commercialization of therapies and cures for the patients who need them.
 
BioNJ’s distinguished Board of Trustees leads and supports this critical mission.  
 
Campbell, who serves as President and Chief Operating Officer of Amicus Therapeutics, and O’Connor, President and Chief Executive Officer of Advaxis, were elected to the BioNJ Board last month.  Both Amicus and Advaxis graduated from CCIT.
 
Nestled in the heart of the state’s “Research Corridor” in North Brunswick, CCIT is advantageously located near world-renowned universities such as Princeton and Rutgers, and a host of pharmaceutical and biotech companies located in the region.
 
Currently home to nearly two-dozen seed stage life sciences companies, CCIT offers its tenants affordable lab and office space, plus a wealth of resources.  These include assistance with identifying funding sources, including state incentives, help making matches to private sector support, and access to small business development resources and administrative support. CCIT also offers discounted rent for the first year for university spinouts.
 
Under Campbell’s direction, Amicus Therapeutics focuses on developing novel, oral therapeutics for the treatment of a range of human genetic diseases.  Amicus became CCIT’s first graduate in 2005 when it moved from the incubator to its current facility in Cranbury to accommodate its growing workforce.  That same year, the company closed on $55 million worth of Series C financing, which included investment from the Garden State Life Sciences Venture Fund, supported by a $10 million investment from the EDA.
 
After graduating from CCIT in 2011, Advaxis moved to Princeton to continue its mission of developing immunotherapies to combat various forms of cancer, including human papillomavirus (HPV)-associated cancers, prostate cancer and certain aggressive types of cancerous solid tumors.  Led by O’Connor, the company was awarded the Farrah Fawcett Foundation’s inaugural “Medical Visionary Angel Award” last year in recognition of its commitment to innovative research.
 
In addition, CCIT graduate Chromocell Corporation’s Chief Executive Officer Christian Kopfli, Esq. was reelected to his position as Secretary of the BioNJ Board. Founded in 2002, Chromocell has grown from a small biotech company into an innovative life sciences company that now employees over 120 people.  The company is focused on discovering new drugs to manage patients’ pain and develops and commercializes novel technologies beneficial to the average consumer, including new flavors, nutritional ingredients and therapeutics.
 
“CCIT plays a vital role in fostering entrepreneurship and innovation, which is critical to the growth of New Jersey’s life sciences ecosystem,” said BioNJ President and CEO Debbie Hart.  “CCIT graduates, such as Amicus Therapeutics, Advaxis and Chromocell, are making a significant impact on the industry and BioNJ is grateful and honored to have their leaders as part of our Board of Trustees.”
 
Several re-elected BioNJ Board members come from companies that have participated in the State’s Technology Business Tax Certificate Transfer (NOL) Program.  Administered by the EDA and the New Jersey Department of Treasury’s Division of Taxation, this competitive program enables eligible technology and biotechnology companies to sell New Jersey tax losses and/or research and development tax credits to raise cash to finance their growth and operations.
 
These include PTC Therapeutics CEO Stuart Peltz, Ph.D., BioNJ’s Chairman of the Board; Drais Pharmaceuticals President and CEO Donna Tempel, Vice chair of the Board; Elusys Therapeutics President and CEO Elizabeth Posillico, Treasurer of the Board; Emisphere Technologies President and CEO Alan L. Rubino; Agile Therapeutics President and CEO Al Altomari; Celldex Therapeutics, Inc. Founder, President, CEO and Director Anthony S. Marrucci; and Soligenix President and CEO Christopher Schaber. Amicus and Advaxis have also benefitted from the NOL program.
 
To learn about the various programs and resources available to support the technology industry, visit http://www.njeda.com/tls and follow @NJEDATech on Twitter and LinkedIn.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Health Care
    Healthcare
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608
732-729-9619